Add to ORKGRecurrent cytogenetic aberrations, genetic mutations and variable gene expression have been consistently recognized in solid cancers and in leukaemia, including in Myelodysplastic Syndromes (MDS). Besides conventional cytogenetics, the growing accessibility of new techniques has led to a deeper analysis of the molecular significance of genetic variations. Indeed, gene mutations affecting splicing genes, as well as genes implicated in essential signalling pathways, play a pivotal role in MDS physiology and pathophysiology, representing potential new molecular targets for innovative therapeutic strategies
Myelodysplastic syndromes (MDS) are heterogeneous myeloid disorders with prevalent mutations in seve...
Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders with heterogeneous presentation, ...
Myelodysplastic syndromes (MDS) are heterogeneous myeloid disorders with prevalent mutations in seve...
Recurrent cytogenetic aberrations, genetic mutations and variable gene expression have been consiste...
Recurrent cytogenetic aberrations, genetic mutations and variable gene expression have been consiste...
none12siRecurrent cytogenetic aberrations, genetic mutations and variable gene expression have been ...
Splicing factor gene mutations are the most frequent mutations found in patients with the myeloid ma...
Splicing factor gene mutations are the most frequent mutations found in patients with the myeloid ma...
Mutations in components of the 3′ mRNA splicing machinery are found in almost 50% of myelodysplastic...
Myelodysplastic syndromes (MDS) are a heterogeneous group of chronic hematological malignancies char...
Myelodysplastic syndromes (MDS) are a heterogeneous group of chronic hematological malignancies char...
Myelodysplastic syndromes (MDS) are a heterogeneous group of chronic hematological malignancies char...
Myelodysplastic syndromes (MDS) are a heterogeneous group of chronic hematological malignancies char...
Accurate pre-mRNA splicing by the spliceosome is a fundamental cellular mechanism required to remove...
A cohort of MDS patients was examined for mutations affecting four splice genes (SF3B1, SRSF2, ZRSR2...
Myelodysplastic syndromes (MDS) are heterogeneous myeloid disorders with prevalent mutations in seve...
Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders with heterogeneous presentation, ...
Myelodysplastic syndromes (MDS) are heterogeneous myeloid disorders with prevalent mutations in seve...
Recurrent cytogenetic aberrations, genetic mutations and variable gene expression have been consiste...
Recurrent cytogenetic aberrations, genetic mutations and variable gene expression have been consiste...
none12siRecurrent cytogenetic aberrations, genetic mutations and variable gene expression have been ...
Splicing factor gene mutations are the most frequent mutations found in patients with the myeloid ma...
Splicing factor gene mutations are the most frequent mutations found in patients with the myeloid ma...
Mutations in components of the 3′ mRNA splicing machinery are found in almost 50% of myelodysplastic...
Myelodysplastic syndromes (MDS) are a heterogeneous group of chronic hematological malignancies char...
Myelodysplastic syndromes (MDS) are a heterogeneous group of chronic hematological malignancies char...
Myelodysplastic syndromes (MDS) are a heterogeneous group of chronic hematological malignancies char...
Myelodysplastic syndromes (MDS) are a heterogeneous group of chronic hematological malignancies char...
Accurate pre-mRNA splicing by the spliceosome is a fundamental cellular mechanism required to remove...
A cohort of MDS patients was examined for mutations affecting four splice genes (SF3B1, SRSF2, ZRSR2...
Myelodysplastic syndromes (MDS) are heterogeneous myeloid disorders with prevalent mutations in seve...
Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders with heterogeneous presentation, ...
Myelodysplastic syndromes (MDS) are heterogeneous myeloid disorders with prevalent mutations in seve...